Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.
Novo Nordisk' obesity pipeline consists of projects addressing both appetite reduction and energy expenditure, with GLP-1 semaglutide topping the list, its CSO says in an interview with Scrip.
Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.
The UK start-up has quickly switched from research services to drug discovery to exploit more fully its novel platform technology for drug screening and development, funded by Syncona and other investors.
Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.
The still somewhat loosely defined concept of 'digital health' continues to take concrete forms through recent deals in Japan, where major pharma firms are building initiatives related mainly to patient well-being.
Following an exchange decision that Samsung BioLogics should remain listed, the company has vowed to improve management transparency by beefing up internal controls and supervision over accounting. The decision is set to ease worries over the possible negative impact of an accounting probe on contract development and manufacturing orders, although the company still faces a court battle with financial authorities over its accounting standards.
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.
O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.